Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct;18(5):263-74.
doi: 10.1177/1358863X13503695. Epub 2013 Sep 19.

n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial

S Marlene Grenon  1 , Christopher D Owens, Hugh Alley, Karen Chong, Priscilla K Yen, William Harris, Millie Hughes-Fulford, Michael S Conte
Affiliations
Randomized Controlled Trial

n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial

S Marlene Grenon et al. Vasc Med. 2013 Oct.

Abstract

Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort.

Trial registration: ClinicalTrials.gov NCT01310270.

Keywords: fatty acids; peripheral artery disease; randomized controlled trials.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest

The authors have no conflicts of interest to declare.

Figures

Figure I
Figure I
OMEGA-PAD trial.
Figure 2
Figure 2
Study protocol.
See this image and copyright information in PMC

References

    1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510–515. - PubMed
    1. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324. - PubMed
    1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386. - PubMed
    1. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119–128. - PubMed
    1. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation. 1990;82:1925–1931. - PubMed

Publication types

Substances

Associated data